Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Change in Cash: 2023-2025

Historic Change in Cash for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $23.4 million.

  • Compass Therapeutics' Change in Cash rose 30.01% to $23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 27.37%. This contributed to the annual value of $19.3 million for FY2024, which is 279.65% up from last year.
  • Per Compass Therapeutics' latest filing, its Change in Cash stood at $23.4 million for Q3 2025, which was up 228.39% from -$18.2 million recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' Change in Cash peaked at $23.4 million during Q3 2025, and registered a low of -$18.2 million during Q2 2025.
  • Its 3-year average for Change in Cash is $1.0 million, with a median of -$2.4 million in 2025.
  • Its Change in Cash has fluctuated over the past 5 years, first spiked by 198.64% in 2024, then slumped by 339.53% in 2025.
  • Compass Therapeutics' Change in Cash (Quarterly) stood at -$6.2 million in 2023, then surged by 198.64% to $6.1 million in 2024, then skyrocketed by 30.01% to $23.4 million in 2025.
  • Its Change in Cash stands at $23.4 million for Q3 2025, versus -$18.2 million for Q2 2025 and -$2.4 million for Q1 2025.